Key result
Coronary microvascular dysfunction linked to ~122% higher MACCE risk specifically in obese STEMI patients.
Why the study?
The prognostic impact of coronary microvascular dysfunction assessed by angio-IMR across obesity categories in STEMI patients remained unclear.
Cohort (n=497)
Yes
Absolute Event Rate: 33.3% vs 15%
p-value: p=0.016
CMD may aid prognostication in obese STEMI; leaves open whether targeting microvascular dysfunction improves outcomes.
Aims This study aimed to assess the association of coronary microvascular dysfunction (CMD) assessed by the angiography‐derived index of microcirculatory resistance (angio‐IMR) with long‐term cardiovascular outcomes in ST‐elevation myocardial infarction (STEMI) patients stratified by obesity categories. Materials and Methods In this multicentre prospective cohort, STEMI patients undergoing primary percutaneous coronary intervention (PPCI) were enrolled. Patients were stratified by obesity categories (healthy weight: BMI < 24 kg/m 2 ; overweight: 24–28 kg/m 2 ; obesity: ≥ 28 kg/m 2 ). CMD was defined as angio‐IMR > 40 U. Results Of 497 STEMI patients, CMD prevalence was comparable across BMI groups ( p = 0.875). The cumulative incidence of MACCE was significantly higher in the CMD group than in the non‐CMD group among patients with obesity (33.3% vs. 15.0%, log‐rank p = 0.016), but not among those with overweight (19.6% vs. 15.9%, log‐rank p = 0.565) and healthy weight (20.7% vs. 17.4%, log‐rank p = 0.673). CMD independently predicted MACCE in obesity (adjusted HR; p = 0.020), with consistent results for continuous angio‐IMR (adjusted HR 1.03, p < 0.001). No associations existed in patients with overweight or healthy weight. Additionally, CMD was associated with a higher prevalence of intramyocardial haemorrhage exclusively in obesity (adjusted OR 4.40, p = 0.003) and overweight (adjusted OR 2.65, p = 0.007). Conclusion CMD assessed by angio‐IMR is an independent predictor of MACCE in STEMI patients with obesity, but not those without obesity. Patients with obesity and STEMI who have CMD may represent a high‐risk subgroup for future trials of microvascular‐protective therapies.
No takes yet. Share an insight, caveat, or question.
Guo et al. (2026) conducted a cohort in ST-elevation myocardial infarction (STEMI) (n=497). Coronary microvascular dysfunction (CMD) assessed by angio-IMR > 40 U vs. Non-CMD was evaluated on MACCE (p=0.016). Coronary microvascular dysfunction (angio-IMR > 40 U) was associated with a higher incidence of MACCE in STEMI patients with obesity (33.3% vs. 15.0%, p=0.016), but not in those without obesity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: